Georgina Long is a medical oncologist and scientist specialising in melanoma. She has led an extensive program of clinical trials, revolutionising the way melanoma is treated worldwide and leading to Australian government funding of ten new melanoma drugs which significantly increase survival. Long published the first research to show a survival improvement in patients with melanoma brain metastasis and led efforts to introduce the first new checkpoint inhibitor drug into clinical oncology in over a decade. Her recent groundbreaking work on the neoadjuvant platform is now revolutionising how operable cancers (melanoma and beyond) are treated. In recognition of the contribution of her outstanding research and work, Professor Long was awarded 2024 Australian of the Year (jointly with colleague Professor Richard Scolyer).